Big Pharma has a hiring problem—and it’s showing up in the patent fine print.
When people talk about “the patent cliff,” they usually mean revenue cliffs: blockbuster drugs losing exclusivity, generics arriving, margins compressing. But there’s another…

Biosimilar sourcing is no longer a procurement exercise—it’s an IP strategy.
If you’re planning a switch from an originator biologic to a biosimilar, the hardest part isn’t finding a supplier. It’s timing the switch so you don’t get blindsided by exc…

Pharma has a familiar playbook: take an old molecule, reframe the evidence, and sell it as something new.
That’s the core tension behind “old drugs, new prices”—and it’s showing up more often as companies repurpose existing therapies for new indication…

Pharma is obsessed with patents—until it’s time to find the people behind them.
Here’s the uncomfortable truth: most “talent searches” in life sciences are still built like job boards. Keywords. Titles. A few familiar institutions. A quick scan of publ…

Pharma has a new playbook for “old” drugs: repackage them as “new” again—and justify premium pricing with a straight face.
That’s the core tension behind the latest discussion from DrugPatentWatch: how companies can take repurposed medicines—therapies …

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s drug strategy is often described in headlines as a “self-reliance” push. But the real story is hiding in plain sight: patent filings.
In a world where supply chains are fragile and regulatory timelines are opaque, the most reliable early-warni…

Big Pharma doesn’t always “win” in court. Sometimes it just keeps the clock running.
Europe’s divisional patent strategy—where companies split one patent application into multiple “divisional” filings—has become a powerful tool to delay final decisions…

Pharma patent litigation used to be a rite of passage—an expensive one.
For years, the industry treated legal spend as an unavoidable cost of doing business: file, fight, appeal, repeat. But the economics are changing fast. According to recent analysis…

PBMs and rebates are no longer “background noise” in pharma—they’re the operating system. If you’re a pharma executive still treating formularies and rebate negotiations as a periodic headache, you’re already behind.
Here’s the uncomfortable truth: the…